DXCM Share Price Performance
US$72.73
-11.40 (-13.55%)
14.7% undervalued intrinsic discount
US$85.24
Fair Value
Price US$72.73
AnalystConsensusTarget US$85.24
AnalystLowTarget US$67.93
Fair ValueUS$85.24
Share Pricen/a
Narrative Update • Jul 11
DexCom, Inc. Stock Price
- 2 Narratives written by author
- 1 Comments on narratives written by author
- 146 Fair Values set on narratives written by author
DXCM Community Narratives
AN
Fair Value
·Fair Value US$85.24 14.7% undervalued intrinsic discount
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
0users have liked this narrative
1users have commented on this narrative
68users have followed this narrative
AN
Fair Value
·Fair Value US$67.93 7.1% overvalued intrinsic discount
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DXCM: Expanding Reimbursement Will Drive Gains Despite Market Uncertainty
DexCom could unlock a wave of new customers as more insurers and health systems cover its glucose sensors, while international adoption and tighter links to apps and wearables deepen day‑to‑day use. The flip side is that tougher price pressure, faster-moving rivals, and execution hiccups—from supply constraints to a CEO handover—could blunt the upside.Read more
AN
US$85.24
14.7% undervalued intrinsic discount
Fair Value
Revenue
11.58% p.a.
Profit Margin
21.34%
Future PE
27.22x
Price in 2029
US$105.75
Type 2 Coverage Expansion And AI Features Will Shape A Balanced Long Term Outlook
DexCom is pushing to bring its glucose sensors to many more people with type two diabetes, but getting newly covered patients to actually start using them may take longer than hoped. New longer-wear sensors and app features could help keep users engaged, yet reimbursement decisions and rising input costs could still reshape growth and profitability.Read more
AN
US$67.93
7.1% overvalued intrinsic discount
Fair Value
Revenue
10.37% p.a.
Profit Margin
18.16%
Future PE
26.35x
Price in 2029
US$84.32
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
DXCM: CONNECT Data In Type 2 Non Insulin Users Will Drive Upside
Fair Value: US$85.24 14.7% undervalued intrinsic discount
68 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
DXCM: Future CGM Adoption And Trial Data Will Test Premium Expectations
Fair Value: US$67.93 7.1% overvalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
DexCom, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 30, 2026
- 2.41
- 61.50%
- 19.31%
- 42.0%
About DXCM
- Founded
- 1999
- Employees
- 11050
- CEO
- WebsiteView website
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
